The full content of Annals is available to subscribers

Subscribe/Learn More  >
Original Research |

Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

Yasuharu Imai, MD; Sumio Kawata, MD; Shinji Tamura, MD; Iwao Yabuuchi, MD; Shuzo Noda, MD; Masami Inada, MD; Yuichi Maeda, MD; Yasuhiro Shirai, MD; Takaaki Fukuzaki, MD; Itaru Kaji, MD; Hideki Ishikawa, MD; Yukihiko Matsuda, MD; Masahiro Nishikawa, MD; Kouichi Seki, MD; and Yuji Matsuzawa, MD
[+] Article, Author, and Disclosure Information

For the Osaka Hepatocellular Carcinoma Prevention Study Group. From Osaka University Medical School, Osaka, Japan. Acknowledgment: The authors thank Hideaki Tsukuma, MD, for his comments on the manuscript. Requests for Reprints: Sumio Kawata, MD, Second Department of Internal Medicine, Osaka University Medical School, 2-2 Yamadaoka, Suita, Osaka 565, Japan. Current Author Addresses: Drs. Imai and Nishikawa: Department of Internal Medicine, Ikeda Municipal Hospital, 3-1-18 Johnan, Ikeda, Osaka 563, Japan.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1998;129(2):94-99. doi:10.7326/0003-4819-129-2-199807150-00005
Text Size: A A A

Background: The effect of interferon therapy on the incidence of hepatocellular carcinoma in chronic hepatitis C is poorly defined.

Objective: To compare the incidence of hepatocellular carcinoma in interferon-treated patients with chronic hepatitis C to that of historical controls and to examine whether response to therapy is related to incidence of hepatocellular carcinoma in patients with chronic hepatitis C.

Design: Retrospective cohort study.

Setting: One university hospital and seven university-affiliated hospitals.

Patients: 419 consecutive patients with chronic hepatitis C who started interferon therapy between January 1992 and December 1993 (interferon group) and 144 patients with chronic hepatitis C who had liver biopsy between January 1986 and December 1989 and did not receive interferon (controls).

Intervention: Patients in the interferon group received human lymphoblastoid interferon, recombinant interferon-α 2a, or recombinant interferon-α 2b for 6 months.

Measurements: The end point was development of hepatocellular carcinoma on abdominal ultrasonography or computed tomography. Sustained response was defined as persistent normalization of alanine aminotransferase (ALT) levels during interferon therapy and follow-up. Relapse was defined as a normal serum ALT level at the end of treatment with an increase to an abnormal level after cessation of treatment. Nonresponse included all other ALT patterns.

Results: Median follow-up in the interferon and control groups was 47.6 and 46.8 months, respectively. During follow-up, hepatocellular carcinoma was found in 28 interferon-treated patients and 19 controls. Cox proportional-hazards regression analysis that included all patients revealed that interferon therapy (P = 0.041), older age (P = 0.003), greater histologic activity (P = 0.029), and higher histologic stage (P = 0.049) were independent factors associated with the development of hepatocellular carcinoma. The risk ratios for development of hepatocellular carcinoma in patients with sustained response, relapse, and nonresponse were 0.06 (95% CI, 0.01 to 0.46), 0.51 (CI, 0.20 to 1.27), and 0.95 (CI, 0.48 to 1.84), respectively, compared with controls.

Conclusions: The incidence of hepatocellular carcinoma was lower in patients with sustained response to interferon therapy than historical controls and nonresponders. Interferon therapy may decrease the risk for hepatocellular carcinoma in patients with chronic hepatitis C.


Grahic Jump Location
Figure 1.
Cumulative incidence of hepatocellular carcinoma (HCC) in interferon-treated patients (dotted line) and historical controls (solid line) with chronic hepatitis C.P

A log-rank test of the two curves showed a significant difference between the two groups ( = 0.040).

Grahic Jump Location
Grahic Jump Location
Figure 2.
Cumulative incidence of hepatocellular carcinoma (HCC) in interferon-treated patients with chronic hepatitis C categorized by sustained response (dashed line), relapse (dotted line), and non-response (solid line).

A log-rank test of the three curves showed a significant difference between these groups (P<0.001).

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.